StoneX reiterates Hold on Beauty Health stock after reverse split
StoneX reiterated a Hold rating on The Beauty Health Company (SKIN) after its 1-for-20 reverse stock split. The stock is down 61% year-over-year, trading at $11.56, but is considered undervalued by InvestingPro. The company is shifting to a medtech-inspired model and expects to return to profitability this year. Q2 2026 revenue missed estimates at $72.1M, but adjusted EBITDA beat guidance at $17.0M.
How this was made
The 30-second read
Why it matters
The split and hold rating provide limited new actionable insight; the primary effect is short-term price adjustment.
Market read
Low relevance for traders; the event is a routine corporate action with no clear catalyst for a directional move.
What to watch
Potential future earnings recovery and margin expansion could outweigh short-term split noise.
Background
The article combines a rating reiteration with details of a recent reverse stock split and Q2 financial results.
Ticker impact
StoneX reiterated a Hold rating after The Beauty Health Company completed a 1-for-20 reverse stock split today.
likely modest pressure as investors digest the split and rating hold.
Reverse splits are typically neutral events; the hold rating adds no new directional bias.
Market effects
Minimal impact on the broader medtech/beauty health sector.
US market only, limited effect.
Low
Counterpoint
Some investors may view the split as a chance to buy at a lower price per share if fundamentals improve.
Key entities
- companyThe Beauty Health Company
NASDAQ-listed medtech/beauty health firm (ticker SKIN).
- analystStoneX
Research firm that issued the Hold rating.
